Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts

Wetherby-based Avacta, in partnership with therapeutic giant Cytiva, is developing a rapid test strip for patient saliva that aims to provide a result in a few minutes, indicating whether the

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2

BBI Solutions is pleased to announce it has been appointed to manufacture the saliva-based rapid SARS-COV-2 antigen test that is being developed by Affimer® biotherapeutics and reagents developer Avacta Group plc

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. What is the objective of the collaboration: The partnership

Avacta Group could earn anything from $1/2bn to $1bn from an extended partnership with LG Chem Life Science, the Massachusetts-based subsidiary of the South Korean LG Group. The windfall stems

vacta Group has announced the expansion of its existing collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group,

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences, the life sciences

South Wales based BBI develops and manufactures raw materials and finished test products for the in-vitro diagnostics market with manufacturing sites in five different countries, spanning four continents. Dr. Mario Gualano, chief